Are increasing 5-year survival rates evidence of success against cancer?

被引:330
作者
Welch, HG
Schwartz, LM
Woloshin, S
机构
[1] Vet Adm Hosp, VA Outcomes Grp, White River Junction, VT USA
[2] Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH USA
[3] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 283卷 / 22期
关键词
D O I
10.1001/jama.283.22.2975
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Increased 5-year survival for cancer patients is generally inferred to mean that cancer treatment has improved and that fewer patients die of cancer. Increased 5-year survival, however, may also reflect changes in diagnosis: finding more people with early-stage cancer, including some who would never have become symptomatic from their cancer. Objective To determine the relationship over time between 5-year cancer survival and 2 other measures of cancer burden, mortality and incidence. Design and Setting Using population-based statistics reported by the National Cancer Institute Surveillance, Epidemiology, and End Results Program, we calculated the change in 5-year survival from 1950 to 1995 for the 20 most common solid tumor types. Using the tumor as the unit of analysis, we correlated changes in 5-year survival with changes in mortality and incidence. Main outcome Measure The association between changes in 5-year survival and changes in mortality and incidence measured using simple correlation coefficients (Pearson and Spearman). Results From 1950 to 1995, there was an increase in 5-year survival for each of the 20 tumor types. The absolute increase in 5-year survival ranged from 3% (pancreatic cancer) to 50% (prostate cancer). During the same period, mortality rates declined for 12 types of cancer and increased for the remaining 8 types. There was little correlation between the change in 5-year survival for a specific tumor and the change in tumor-related mortality (Pearson r=.00; Spearman r=-.07). On the other hand, the change in 5-year survival was positively correlated with the change in the tumor incidence rate (Pearson r=+.49; Spearman r=+.37). Conclusion Although 5-year survival is a valid measure for comparing cancer therapies in a randomized trial, our analysis shows that changes in 5-year survival over time bear little relationship to changes in cancer mortality. Instead, they appear primarily related to changing patterns of diagnosis.
引用
收藏
页码:2975 / 2978
页数:4
相关论文
共 6 条
[1]   PROGRESS AGAINST CANCER [J].
BAILAR, JC ;
SMITH, EM .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (19) :1226-1232
[2]   ADVANCES IN DIAGNOSTIC-IMAGING AND OVERESTIMATIONS OF DISEASE PREVALENCE AND THE BENEFITS OF THERAPY [J].
BLACK, WC ;
WELCH, HG .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (17) :1237-1243
[3]  
KOLATA G, 1999, NY TIMES 1027, pA19
[4]  
*SEER, 2000, SEER CANC STAT REV 1
[5]  
SONDIK EJ, 1990, J NATL CANCER I, V82, P825
[6]  
*US DEPT HHS, 1999, CANC SURV